Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 24, 2026 16:05 ET | Source: Intellia Therapeutics, Inc.

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

World’s first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE)...
April 24, 2026 15:58 ET | Source: FDA

FDA Accelerates Action on Treatments for Serious Mental Illness Following Executive Order

White Oak, Md., April 24, 2026 (GLOBE NEWSWIRE) -- President Trump on April 18 issued an Executive Order directing the U.S. Department of Health and Human Services to accelerate access to treatments...
April 24, 2026 13:10 ET | Source: RTA Outdoor Living

RTA Outdoor Living Launches 'Health Haven' YouTube Special on Backyard Design and Health

Greenland, N.H., April 24, 2026 (GLOBE NEWSWIRE) -- RTA Outdoor Living has released Health Haven, a YouTube special exploring how residential outdoor environments influence stress, recovery,...
April 24, 2026 11:23 ET | Source: King Faisal Specialist Hospital & Research Centre

KFSH Scales Genomic Medicine from Research to Clinical Decision-Making

RIYADH, Saudi Arabia, April 24, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH) is advancing a clinically integrated model of genomic medicine, demonstrating how...
April 24, 2026 11:00 ET | Source: Indivior Pharmaceuticals Inc.

Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder

A collaboration with Virginia Tech supports recognizing remission as a treatment outcome—capturing symptoms, quality of life, and functional outcomes—beyond abstinence aloneOf all MOUD, monthly...
April 24, 2026 10:43 ET | Source: A.D.A.M. Innovations

DNA DAY™ 2026: GeneLife Advances GeneAI Forecast with 15 Predictive Models and Enhanced Lifestyle Integration

GeneLife Advances GeneAI Forecast with 15 Predictive Models and Enhanced Lifestyle Integration
April 24, 2026 10:37 ET | Source: Medicana Health Group

Medicana Health Group Launches HPV Vaccination and Cervical Cancer Awareness Campaign, Advancing Prevention Through Regular Check-Ups

Photo: Medicana Ataköy Hospital in Istanbul via FL Comms ISTANBUL, Türkiye, April 24, 2026 (GLOBE NEWSWIRE) -- Medicana Health Group has launched a new HPV vaccination and cervical cancer...
April 24, 2026 08:30 ET | Source: Gain Therapeutics, Inc.

Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026

BETHESDA, Md., April 24, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of...
April 24, 2026 08:00 ET | Source: Kyowa Kirin

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been...
April 24, 2026 07:38 ET | Source: Amphista Therapeutics

Amphista Therapeutics announces presentation of new preclinical data from its SMARCA2 and TEAD Targeted Glue™ degrader programs at AACR 2026, and publication of the first data on its TEAD program

Cambridge, UK, 24th April 2026 - Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of non-cereblon/non-VHL Targeted Glue™ degraders, today announces the...